Axia Group (AGIJ) Collagenna Skin Care Reaches Agreement With Prime Pharmaceutical Corporation (Allegiances Equity Corporation) for Marketing and Development of Psoriasis Products
(firmenpresse) - OTTAWA, ONTARIO -- (Marketwire) -- 08/10/11 -- Axia Group (PINK SHEETS: AGIJ) () Collagenna Skin Care Products is pleased to announce that is has reached an agreement with Prime Pharma, a subsidiary of the TSE publicly traded company Allegiance Equity Corporation for the marketing and development of Mahonia Products which have been clinically proven to help relieve the symptoms related to psoriasis. Prime Pharma's premier product is the Relieva cream, an over the counter psoriasis cream which has been reformulated into a more effective product. The agreement is based upon a joint venture for worldwide, non-internet marketing sales of the Mahonia extract product line, both present and future products.
Axia's CEO, Michael Arnkvarn states, "Allegiance Equity Group has always operated through licensing agreements but we did not feel that a license at this time was in the best interests for our company. We were able to come up with a formula which will allow us to develop the retail/wholesale market without financial stress and both parties will reap the benefits. We have identified some distinct opportunities for both the retail and clinical markets. Our agreement will allow us access to worldwide patents as well as new patentable technology which we plan to proceed with in the very near future. Mahonia is a proven active ingredient that is extremely effective with zero toxicity and irritancy a major advantage over steroids and other prescription products for the treatment of psoriasis eczema and other problem skin conditions. Prime Pharma possesses a patented extract with which we plan to find some innovative ways to help distinguish our company from the competition.
"We will soon commence a clinical trial of our own to validate our preliminary testing and we hope to publish results in the next 30 days. We have started the process of getting the necessary regulatory paperwork in place in our name which will allow us to market Relieva in both Canada and the US. We do not foresee any major hurdles and we expect the process to take around 60 days. In the meantime we will initiate marketing efforts immediately.
"Problematic skin is a highly sensitive issue and people are always looking for solutions that work. We feel that with the right combination of technology, clinical and retail products which will separate use from the pack and open up new possibilities to further develop our clinics and business opportunity sales."
An Independent report (Research and Markets) of 2004 on world-wide psoriasis prescription market concluded this market to grow at compound annual rate of 23.6% to over $3.1B worldwide by 2009. According to Global Industry analysts Inc., Global psoriasis drugs market will exceed $7.3 billion dollars by 2015, with no satisfactory treatment in sight. The use of Over the Counter drugs and alternative treatments is widespread (32% of patients are not under physician care) and makes the actual market size significantly higher than stated above.
Collagenna Skin Care Products specializes in Anti-aging products with an emphasis on Collagen stimulation both topically and internally. The company sells its products mainly through its specialized skin care clinics through its every expanding network of distribution partners.
More details and updates will be provided shortly and on a timely basis.
Safe Harbor Statement
Information in this news release may contain statements about future expectations, plans, prospects or performance of Axia Group Inc., that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be," "expects," "may affect," "believed," "estimate," "project" and similar words and phrases are intended to identify such forward-looking statements. Axia Group Inc. cautions you that any forward-looking information provided by or on behalf of Axia Group Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Axia Group Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Axia Group Inc.'s control. In addition to those discussed in Axia Group Inc.'s press releases, public filings, and statements by Axia Group Inc.'s management, including, but not limited to, Axia Group Inc.'s estimate of the sufficiency of its existing capital resources, Axia Group Inc.'s ability to raise additional capital to fund future operations, Axia Group Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Axia Group Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Axia Group Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
Contacts:
Axia Group Inc.
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 10.08.2011 - 13:45 Uhr
Sprache: Deutsch
News-ID 1029473
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
OTTAWA, ONTARIO
Phone:
Kategorie:
Personal Care & Fitness
Anmerkungen:
Diese Pressemitteilung wurde bisher 166 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Axia Group (AGIJ) Collagenna Skin Care Reaches Agreement With Prime Pharmaceutical Corporation (Allegiances Equity Corporation) for Marketing and Development of Psoriasis Products
"
steht unter der journalistisch-redaktionellen Verantwortung von
Axia Group Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
